During the COVID-19 pandemic, the Chinese Health Insurance Bureau has made long-prescription adjustments to provide protection for breast cancer endocrine therapy, including aromatase inhibitors and SERMs (selective estrogen receptor modulators). This evidence concerns the gene CYP19A1 and breast cancer.